presentation for statisitics group A.pptx

presentation for statisitics

1. Group A; Project name: Statistical Analysis & implementation for Products under Accelerated study Dr. Yasser Yakout

2. Table for products name, loading date, results of assay Name of the product Start date of Accelerated study Assay at zero time (%) Assay after 6 months (%) Acceptable difference NMT 5.0 % Alkapride 50 mg FCT 19/10/2022 97.71 92.92 4.8 Arkadolow 1000 mg Tablet 20/07/2023 98.20 100.70 -2.5 Blokatens HCT 5/12.5/160 FCT 14/08/2023 98.08 96.20 1.9 Blokatens HCT 10/25/160 FCT 14/08/2023 100.00 96.23 3.8 Blokatens 10/160 FCT 16/11/2023 100.04 98.82 1.2 Blokatens 5/80 FCT 16/11/2023 101.30 101.15 0.1 Blokatens 5/160 FCT 16/11/2023 98.42 98.70 -0.3 Chartoreg 40 mg Tab 14/08/2023 96.93 97.61 -0.7 Chartoreg 80 mg Tab 20/02/2023 103.17 101.15 2.0 Chartoreg plus 40/12.5 mg Bilayer Tab 24/05/2023 99.46 99.73 -0.3 Chartoreg plus 80/25 mg Bilayer Tab 29/03/2023 97.35 99.91 -2.6 Chartoreg Co 10/80 mg Bilayer Tab 27/07/2023 99.12 99.54 -0.4 Chartoreg Co 5/80 mg Bilayer Tab 27/07/2023 99.87 98.63 1.2 Chartoreg Co 5/40 mg Bilayer Tab 5/6/2023 101.51 102.35 -0.8 Chartoreg Co 10/40 mg Bilayer Tab 27/07/2023 100.23 99.74 0.5 Chartoreg Trio 5/12.5/80 mg Bilayer Tab 30/04/2023 97.62 98.91 -1.3 Downoprazol 20/1100mg HGC 13/10/2022 97.11 94.44 2.7 Downoprazol 40/1100mg HGC 13/10/2022 100.26 98.82 1.4 Downoprazol 20mg/1680mg Powder for Oral Suspension in Packet 28/11/2022 96.81 96.92 -0.1 Downoprazol 40mg/1680mg Powder for Oral Suspension in Packet 28/11/2022 95.73 95.91 -0.2 Duloxeprine 20mg DR HGC 7/11/2022 97.50 99.40 -1.9 Duloxeprine 30mg DR HGC 7/11/2022 102.43 105.10 -2.7 Geskaprofen 25 mg FCT 14/02/2023 98.92 95.80 3.1 Itrafungex 100 mg HGC 24/11/2022 94.20 94.30 -0.1 Levohistam 5 mg FCT 25/09/2023 100.21 97.66 2.6 Moxavidex 400mg FCT 17/11/2022 100.14 97.55 2.6 Nanazoxid 100mg/5ml Susp. 15/09/2022 99.75 95.57 4.2 Nanazoxid 500mg FCT 13/10/2022 97.51 97.21 0.3 Torseretic 5mg Tablet 23/11/2022 103.13 101.28 1.8 Torseretic 10mg Tablet 23/11/2022 98.42 94.81 3.6 Torseretic 20mg Tablet 23/11/2022 98.53 97.17 1.4 Torseretic 60mg Tablet 30/04/2023 98.58 100.32 -1.7 Torseretic 100mg Tablet 23/11/2023 97.75 97.57 0.2 Levohistam Oral drop 14/09/2023 94.95 95.56 -0.6 Levohistam syrup 30/08/2023 96.84 96.13 0.7 Qulaperfen oral suspension 31/07/2022 97.48 97.17 0.3 Urginafect 5 mg FCT 16/03/2023 100.94 100.29 0.6 Urginafect 10 mg FCT 16/03/2023 96.19 99.57 -3.4 Urginafect oral suspension 6/9/2023 99.92 101.34 -1.4 Utopia cold POS 29/03/2023 96.65 100.69 -4.0 Vonopravin 10 mg Tab 23/03/2023 100.84 101.69 -0.8 Vonopravin 20 mg Tab 23/03/2023 106.68 102.17 4.5

3. Data Types for Statistical Analysis: Descriptive Data Analysis:

4. Histogram (with Normal curve):

5. Histogram for normal curve for assay 6 month

6. Histogram of acceptable difference

7. Conclusion : Based on the description of the histogram with a normal curve : The histogram represents the distribution of assay at zero time from 94.2 % to 106.7% The mean assay is 98.96 % , and the standard deviation is 2.38 , indicating a relatively tight distribution around the mean. The histogram represents the distribution of assay after 6 months from 92.92 % to 105.1% The mean assay is 98.49 % , and the standard deviation is 2.583 , indicating a relatively tight distribution around the mean. The mean acceptable difference is 0.4702 , and the standard deviation is 2.146 , indicating a relatively tight distribution around the mean. The normal curve suggests that the data is approximately normally distributed. The number of observations (N) is 42, which is a reasonable sample size for statistical analysis.

8. Boxplot:

9. Conclusion : Based on the statistical test results you’ve provided: Overall, the data appears to be well-distributed with a good fit to the normal curve, suggesting that the process being measured is under control.

10. Hypothesis test: Two-Sample T-Test and CI: Two-Sample T-Test and CI:

11. Conclusion: Based on the statistical data provided for the hypothesis test: T-Value : The T-Value is 0.87, which is not significantly high. P-Value : The P-Value is 0.194, which is more than any common alpha level (e.g., 0.05, 0.01). There is strong statistical evidence to accept the null hypothesis.

12. Presented by : Group A Dr. Mohamed Ahmed Ali : 23128502 Dr . Hazem Labeib : 23128509 Dr. Mahmoud Ashraf Ibrahim : 23128505